Shelby Harrington, RN, supports clients in navigating the transition to value-based care with a focus on clinical quality, strategy, and digital transformation.

In recent projects, Shelby has helped life sciences manufacturers develop value-based care strategies by using mixed-methods research to characterize patient-centric outcomes linked with their products (e.g., improved mental health, relationships, and employment, and ability to work and parent), particularly for rare, chronic, and degenerative diseases. These strategies have supported product pricing and formulary placement and overcome coverage barriers, such as prior authorization, for client assets. Shelby has also developed claims data analysis tools that can be used to advise providers on how to achieve value-based contracting targets (e.g., decreased utilization of expensive treatment in high-need patient populations).

Before joining Avalere, Shelby led clinical product and strategy at Nurx, a direct-to-consumer telemedicine startup. Previously, she served as senior product director for quality and regulatory technology at Premier, Inc., overseeing hospital regulatory products, provider registries, provider MIPS solutions, and value analytics products. Before that, Shelby worked as director of clinical excellence for the Advisory Board Company’s Crimson Population Health suite where she led deployment of evidence-based care plans and launched a population health quality reporting solution. Shelby began her career at Carolinas HealthCare System—now Atrium Health—as a staff nurse in orthopedics and trauma care.

Shelby holds a bachelor’s degree in public policy analysis from the University of North Carolina at Chapel Hill and bachelor’s and master’s degrees in nursing from Virginia Commonwealth University.

Authored Content


The COVID-19 pandemic has catalyzed the growth of hybrid care delivery models, highlighting the need for clinical guidance and stakeholder agility.

Traditional health technology assessments fall short in accounting for how therapy addresses the total burden of illness experienced by affected individuals.

The end of the public health emergency (PHE) raises policy questions around implications for reimbursement, patient access, and operationalization of telehealth service delivery.

Avalere experts will discuss patient-centric value frameworks, their utility to different stakeholders, and how they can drive the transformation to a patient-centered, equitable health system at the AMCP Nexus 2022 conference.

Tune into the second episode in the Avalere Health Essential Voice podcast series focused on the how CMS and Medicare coverage decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs)that have coverage with evidence development (CED) requirements, how FDA and CMS’s evidence questions can be complimentary, and the ways in which manufacturer evidence generation plans can address those goals, using the NCD on monoclonal antibodies for Alzheimer's disease as an example.

Tune into the second episode in the Avalere Health Essential Voice podcast series focused on the how CMS and Medicare coverage decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs)that have coverage with evidence development (CED) requirements, how FDA and CMS’s evidence questions can be complimentary, and the ways in which manufacturer evidence generation plans can address those goals, using the NCD on monoclonal antibodies for Alzheimer's disease as an example.

The final CMS NCD for amyloid beta-targeting monoclonal antibodies for Alzheimer’s Disease establishes a dual pathway to Medicare coverage based on FDA approval and likely creates access and operational challenges for stakeholders.

A nationwide shortage of clinical and non-clinical professionals is straining the healthcare industry. Every part of the health ecosystem is making contingency plans for this ongoing and worsening labor shortage. Solutions range from traditional market approaches of wages and benefits to innovative staffing activities and advocating for policy changes.

Prescription Digital Therapeutics (PDTs) are a growing and unique treatment modality that can provide expanded options for treatment to patients. As the landscape for these treatments develop across multiple therapeutic areas, challenges related to coverage, reimbursement, and access will need to be solved to advance broader adoption and utilization across key stakeholders.